A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
D015746:Abdominal Pain / Q000139:chemically induced; D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy*; D010054:Brief Psychiatric Rating Scale; D002648:Child; D002675:Child, Preschool; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010349:Patient Compliance; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011446:Prospective Studies; D012720:Severity of Illness Index; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects